Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Pancreatic Cancer | Research

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy

Authors: Enliang Li, Xing Huang, Gang Zhang, Tingbo Liang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Dysregulated expression and activation of receptor tyrosine kinases (RTKs) are associated with a range of human cancers. However, current RTK-targeting strategies exert little effect on pancreatic cancer, a highly malignant tumor with complex immune microenvironment. Given that immunotherapy for pancreatic cancer still remains challenging, this study aimed to elucidate the prognostic role of RTKs in pancreatic tumors with different immunological backgrounds and investigate their targeting potential in pancreatic cancer immunotherapy.

Methods

Kaplan–Meier plotter was used to analyze the prognostic significance of each of the all-known RTKs to date in immune “hot” and “cold” pancreatic cancers. Gene Expression Profiling Interactive Analysis-2 was applied to assess the differential expression of RTKs between pancreatic tumors and normal pancreatic tissues, as well as its correlation with immune checkpoints (ICPs). One hundred and fifty in-house clinical tissue specimens of pancreatic cancer were collected for expression and correlation validation via immunohistochemical analysis. Two pancreatic cancer cell lines were used to demonstrate the regulatory effects of RTKs on ICPs by biochemistry and flow cytometry. Two in vivo models bearing pancreatic tumors were jointly applied to investigate the combinational regimen of RTK inhibition and immune checkpoint blockade for pancreatic cancer immunotherapy.

Results

MET was identified as a pancreatic cancer-specific RTK, which is significantly associated with prognosis in both immune “hot” and “cold” pancreatic cancers. MET was observed to be highly upregulated in pancreatic cancer tissues, and positively correlated with PD-L1 levels. Elevated MET and PD-L1 expressions were closely associated with lymph node metastasis, tumor TNM stage, and overall survival in pancreatic cancer. Mechanistically, MET could interact with PD-L1, and maintain its expression level in multiple ways. MET deficiency was found to facilitate lymphocyte infiltration into pancreatic tumors. Finally, significant benefits of combining MET inhibition with PD-1/PD-L1 blockage were verified in both orthotopic and subcutaneous mouse models of pancreatic cancer.

Conclusions

This study systematically investigated the potential effectiveness of a novel pancreatic cancer immunotherapy targeting RTKs, and revealed the function of MET in PD-L1 regulation as well as the combined therapeutic efficacy of MET and PD-L1 in pancreatic cancer.

Available only for authorised users

Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008–20. https://doi.org/10.1016/S0140-6736(20)30974-0 [published Online First: 2020/07/01].CrossRefPubMed

Collisson EA, Bailey P, Chang DK, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207–20. https://doi.org/10.1038/s41575-019-0109-y [published Online First: 2019/02/06].CrossRefPubMed

Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. https://doi.org/10.1038/nature16965 [published Online First: 2016/02/26].CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210.CrossRefPubMed

Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89. https://doi.org/10.3322/caac.21349.CrossRefPubMed

Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. https://doi.org/10.1158/0008-5472.CAN-14-0155.CrossRefPubMed

Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol. 2020. https://doi.org/10.1038/s41571-020-0363-5 [published Online First: 2020/05/14].CrossRefPubMedPubMedCentral

Huang X, Tang T, Wang X, et al. Calreticulin couples with immune checkpoints in pancreatic cancer. Clin Transl Med. 2020;10(1):36–44. https://doi.org/10.1002/ctm2.10 [published Online First: 2020/06/09].CrossRefPubMedPubMedCentral

Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat Immunol. 2020. https://doi.org/10.1038/s41590-020-0761-y [published Online First: 2020/08/19].CrossRefPubMed

10.

Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–34. https://doi.org/10.1016/j.cell.2010.06.011 [published Online First: 2010/07/07].CrossRefPubMedPubMedCentral

11.

Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades. Cold Spring Harb Perspect Biol. 2014;6(3). https://doi.org/10.1101/cshperspect.a008912 [published Online First: 2014/03/05].

12.

Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 1990;61(2):203–12. https://doi.org/10.1016/0092-8674(90)90801-k [published Online First: 1990/04/20].CrossRefPubMed

13.

Bergeron JJ, Di Guglielmo GM, Dahan S, et al. Spatial and temporal regulation of receptor tyrosine kinase activation and intracellular signal transduction. Annu Rev Biochem. 2016;85:573–97. https://doi.org/10.1146/annurev-biochem-060815-014659 [published Online First: 2016/03/30].CrossRefPubMed

14.

Paul MD, Hristova K. The RTK interactome: overview and perspective on RTK heterointeractions. Chem Rev. 2019;119(9):5881–921. https://doi.org/10.1021/acs.chemrev.8b00467 [published Online First: 2018/12/28].CrossRefPubMed

15.

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. https://doi.org/10.1186/s12943-018-0782-4 [published Online First: 2018/02/20].CrossRefPubMedPubMedCentral

16.

Jiao Q, Bi L, Ren Y, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer. 2018;17(1):36. https://doi.org/10.1186/s12943-018-0801-5 [published Online First: 2018/02/20].CrossRefPubMedPubMedCentral

17.

Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48. https://doi.org/10.1038/s41575-018-0005-x [published Online First: 2018/05/03].CrossRefPubMed

18.

Huang X, Li E, Shen H, et al. Targeting the HGF/MET axis in cancer therapy: challenges in resistance and opportunities for Improvement. Front Cell Dev Biol. 2020;8:152. https://doi.org/10.3389/fcell.2020.00152.CrossRefPubMedPubMedCentral

19.

Huang X, Zhang G, Bai X, et al. Reviving the role of MET in liver cancer therapy and vaccination: an autophagic perspective. Oncoimmunology. 2020;9(1):1818438. https://doi.org/10.1080/2162402x.2020.1818438.CrossRefPubMedPubMedCentral

20.

Huang X, Gan G, Wang X, et al. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019;15(7):1258–79. https://doi.org/10.1080/15548627.2019.1580105 [published Online First: 2019/02/23].CrossRefPubMedPubMedCentral

21.

Modica C, Tortarolo D, Comoglio PM, et al. MET/HGF co-targeting in pancreatic cancer: a tool to provide insight into the tumor/stroma crosstalk. Int J Mol Sci. 2018;19(12). https://doi.org/10.3390/ijms19123920 [published Online First: 2018/12/14].

22.

Pennacchietti S, Cazzanti M, Bertotti A, et al. Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. Cancer Res. 2014;74(22):6598–609.CrossRefPubMed

23.

Noguchi K, Konno M, Eguchi H, et al. c-Met affects gemcitabine resistance during carcinogenesis in a mouse model of pancreatic cancer. Oncol Lett. 2018;16:1892–8. https://doi.org/10.3892/ol.2018.8793.

24.

Tomihara H, Yamada D, Eguchi H, et al. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci. 2017;108(3):398–407. https://doi.org/10.1111/cas.13159.CrossRefPubMedPubMedCentral

25.

Rucki AA, Xiao Q, Muth S, et al. Dual inhibition of hedgehog and c-Met pathways for pancreatic cancer treatment. Mol Cancer Ther. 2017;16(11):2399–409. https://doi.org/10.1158/1535-7163.MCT-16-0452 [published Online First: 2017/09/03].CrossRefPubMedPubMedCentral

26.

Huang X, Xu X, Wang X, et al. The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination. Signal Transduct Target Ther. 2020;5(1):122. https://doi.org/10.1038/s41392-020-0179-x [published Online First: 2020/08/09].CrossRefPubMedPubMedCentral

27.

Baumeister SH, Freeman GJ, Dranoff G, et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539–73. https://doi.org/10.1146/annurev-immunol-032414-112049 [published Online First: 2016/03/02].CrossRefPubMed

28.

Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–22. https://doi.org/10.1016/j.immuni.2007.05.016 [published Online First: 2007/07/17].CrossRefPubMedPubMedCentral

29.

Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. https://doi.org/10.1056/NEJMoa1302369 [published Online First: 2013/06/04].CrossRefPubMedPubMedCentral

30.

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665 [published Online First: 2015/09/26].CrossRefPubMedPubMedCentral

31.

Zheng L. PD-L1 expression in pancreatic cancer. J Natl Cancer Inst. 2017;109(6). https://doi.org/10.1093/jnci/djw304 [published Online First: 2017/01/31].

32.

Foley K, Kim V, Jaffee E, et al. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016;381(1):244–51.CrossRefPubMed

33.

Sahin IH, Askan G, Hu ZI, et al. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? Ann Oncol. 2017;28(12):2950–61.CrossRefPubMedPubMedCentral

34.

Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res. 2015;3(4):399–411.CrossRefPubMedPubMedCentral

35.

Pan Y, Fei Q, Xiong P, et al. Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1. Oncoimmunology. 2019;8(5):e1581529. https://doi.org/10.1080/2162402X.2019.1581529.

36.

Mace TA, Shakya R, Pitarresi JR, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67(2):320–32. https://doi.org/10.1136/gutjnl-2016-311585.CrossRefPubMed

37.

Nagy A, Lanczky A, Menyhart O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. https://doi.org/10.1038/s41598-018-27521-y [published Online First: 2018/06/17].CrossRefPubMedPubMedCentral

38.

Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60. https://doi.org/10.1093/nar/gkz430 [published Online First: 2019/05/23].

39.

Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-102. https://doi.org/10.1093/nar/gkx247 [published Online First: 2017/04/14].CrossRefPubMedPubMedCentral

40.

Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8. https://doi.org/10.1038/s41587-020-0546-8 [published Online First: 2020/05/24].

41.

Chen Q, Wang J, Zhang Q, et al. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Br J Cancer. 2019;121(9):786–95. https://doi.org/10.1038/s41416-019-0595-2.CrossRefPubMedPubMedCentral

42.

Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–65. https://doi.org/10.1038/35077225 [published Online First: 2001/05/18].CrossRefPubMed

43.

Guardiola S, Varese M, Sanchez-Navarro M, et al. A third shot at EGFR: new opportunities in cancer therapy. Trends Pharmacol Sci. 2019;40(12):941–55. https://doi.org/10.1016/j.tips.2019.10.004 [published Online First: 2019/11/11].CrossRefPubMed

44.

Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011;17(22):7127–38. https://doi.org/10.1158/1078-0432.CCR-11-1157.CrossRefPubMed

45.

Baltschukat S, Engstler BS, Huang A, et al. Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res. 2019;25(10):3164–75. https://doi.org/10.1158/1078-0432.CCR-18-2814.CrossRefPubMed

46.

Mezzadra R, Sun C, Jae LT, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549(7670):106–10. https://doi.org/10.1038/nature23669 [published Online First: 2017/08/17].CrossRefPubMedPubMedCentral

47.

Burr ML, Sparbier CE, Chan YC, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549(7670):101–5. https://doi.org/10.1038/nature23643 [published Online First: 2017/08/17].

48.

Li H, Li CW, Li X, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156(6):1849-61 e13. https://doi.org/10.1053/j.gastro.2019.01.252 [published Online First: 2019/02/04].

49.

Kammerer-Jacquet SF, Medane S, Bensalah K, et al. Correlation of c-MET expression with PD-L1 expression in metastatic clear cell renal cell carcinoma treated by sunitinib first-line therapy. Target Oncol. 2017;12(4):487–94. https://doi.org/10.1007/s11523-017-0498-1.CrossRefPubMed

50.

Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22(10):2329–34.

51.

Abiko K, Matsumura N, Hamanishi J, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112(9):1501–9. https://doi.org/10.1038/bjc.2015.101.CrossRefPubMedPubMedCentral

52.

Lee SJ, Jang BC, Lee SW, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580(3):755–62. https://doi.org/10.1016/j.febslet.2005.12.093.CrossRefPubMed

53.

Dorand RD, Nthale J, Myers JT, et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016;353(6297):399–403. https://doi.org/10.1126/science.aae0477.CrossRefPubMedPubMedCentral

54.

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56.CrossRefPubMed

55.

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1.

56.

Li CW, Lim SO, Xia W, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.CrossRefPubMedPubMedCentral

57.

Li CW, Lim SO, Chung EM, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187-201.e10.CrossRefPubMedPubMedCentral

58.

Vansteenkiste JF, Van De Kerkhove C, Wauters E, et al. Capmatinib for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2019;19(8):659–71. https://doi.org/10.1080/14737140.2019.1643239.CrossRefPubMed

59.

Qin S, Chan SL, Sukeepaisarnjaroen W, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1–12. https://doi.org/10.1177/1758835919889001.CrossRef

60.

Martin V, Chiriaco C, Modica C, et al. Met inhibition revokes IFNgamma-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019;120(5):527–36. https://doi.org/10.1038/s41416-018-0315-3.CrossRefPubMedPubMedCentral

61.

Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. https://doi.org/10.1186/s12943-019-0974-6 [published Online First: 2019/03/31].CrossRefPubMedPubMedCentral

Title: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
Authors: Enliang Li
Xing Huang
Gang Zhang
Tingbo Liang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02055-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis

Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer

Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past

A preliminary study of micro-RNAs as minimally invasive biomarkers for the diagnosis of prostate cancer patients

The emerging role of β-secretases in cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer